Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition - Wikidata - awgldk - TriplyDB

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

http://www.wikidata.org/entity/Q36822126

about

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma Pathways and therapeutic targets in melanoma Tumour heterogeneity and the evolution of polyclonal drug resistance Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center RAF inhibitors that evade paradoxical MAPK pathway activation RASopathic skin eruptions during vemurafenib therapy Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Drug safety evaluation of vemurafenib in the treatment of melanoma.Evaluating biomarkers in melanoma.No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.Analysis of dermatologic events in vemurafenib-treated patients with melanoma Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient.Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.Molecular targeted therapies in metastatic melanoma.The Conundrum of Genetic "Drivers" in Benign Conditions.Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.Vemurafenib for the treatment of melanoma.New therapeutic options in systemic treatment of advanced cutaneous melanoma.Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.Update on the targeted therapy of melanoma.Dermatological adverse events from BRAF inhibitors: a growing problem.Skin toxicity of targeted cancer agents: mechanisms and intervention.Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Melanoma mutagenesis and aberrant cell signaling.Mechanism and consequences of RAF kinase activation by small-molecule inhibitors The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.Managing the skin toxicities from new melanoma drugs.Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Dermatological toxicity associated with targeted therapies in cancer: optimal management.

P2860

Q26752774-C7A3B584-EC29-4F4F-8133-E8AB4940587D Q26795510-DBFF8EB4-ABD4-489E-BFFC-8E4F172DBA95 Q26865736-72F517B0-139E-4DF3-AF2F-FE90BDE9CE5B Q26866803-F46ACEDC-DB4C-42D1-97F7-8AA07D78C546 Q27276774-985A3044-C545-41EE-9FA0-DFA62C992B4A Q27314686-A8985D38-40BD-400F-B3B7-9635B02C5E97 Q27702299-CBDF922F-2358-45B0-AD28-A8612B19816F Q28488013-49603395-1DDC-4B97-8CFD-BF58192EFB6E Q28554490-6A4C48C7-EEF8-4E39-83A8-4CA0D174E36D Q30313298-A12515B9-0310-4748-A7F2-E547AE358914 Q34341465-636DC277-C952-46B2-B53F-E6793D37406C Q34642874-B4972898-B0D2-42A3-B1CE-28797DC98542 Q34653547-658C91A4-891D-4514-88F9-11B255B46E21 Q35005677-2440E43A-1C76-4D11-A088-0AE2CF01B5F7 Q35013602-7534A631-EACC-401F-9CE9-3D2402053BDD Q35073752-6A302B7A-F2FD-4287-8580-9568D88563BA Q35140116-5F2AF61C-CB91-483F-A10D-515ADB242AEB Q36714398-88A473E0-0052-4D57-8585-30D69422A4C4 Q36743955-E5356D7B-8053-4F6E-B190-06AF24614396 Q36871242-AEBC4E4A-036B-47E2-95E0-46B541C0668D Q36984179-FDFAF064-5ABE-48DA-994A-429ADD403AFF Q37245787-1638900A-6728-41A3-8EC9-CE87716EC7C5 Q37451255-7DEE9F1D-9E80-47E9-A6D9-A94FA7A3525D Q37689575-74DC57AD-F54D-4464-B2C9-ED8092CC7E64 Q37697778-C79340DE-9027-46AC-8A21-4BD4FC700182 Q38036715-D8A6A50F-1BF3-4A16-A2EF-417A8AA6F92D Q38055208-036CF1C9-3700-449C-B50D-AF3257E9CDB1 Q38065194-564464BA-6DD5-4F4C-A10B-151874661538 Q38068205-43CD6606-74FE-44BF-8C03-12E6E123F6F3 Q38082713-62AB96C0-245F-4C0D-81BD-558F846AE98C Q38086762-5EE61FF2-9AFF-4D60-8E8E-1DE231A70B0B Q38125504-5E63431F-9328-4B50-8E14-C7884ADF7E53 Q38139282-27BC10C1-00A9-4BB5-A7FA-FA177AACC9D2 Q38146707-F138DFF0-2549-442A-BA4D-B001EE1D53C1 Q38197024-DB860EE9-CEC8-4E4D-80EE-0786112C0065 Q38203019-2812B65D-7508-4B8B-A7FC-B524A13090B9 Q38215416-2087B4D5-909A-42A9-9671-23FE8AD7FC1B Q38218298-D7D9B246-40E0-41E5-8F0B-C4887B3C7C4C Q38228386-AB08258D-479A-4228-87C5-39136F207737 Q38239381-8DD0A3E2-D6B0-4571-A660-BF52041028B1

P2860

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

http://www.wikidata.org/entity/Q36822126

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Atypical melanocytic prolifera ...... oing selective BRAF inhibition

@en

type

label

Atypical melanocytic prolifera ...... oing selective BRAF inhibition

@en

prefLabel

Atypical melanocytic prolifera ...... oing selective BRAF inhibition

@en

P1433

Q36822126-2F2FAB05-5D67-45C2-B01D-B3C594BEEAB5

P1476

Q36822126-A1DD3273-8269-40B5-8BB5-3F5273B5A85F

P2093

Q36822126-04FDC49A-6971-4623-A26A-077119AFEA19

Q36822126-3450E0B4-3680-4761-ABD0-0166778BC713

Q36822126-35767282-E5A9-45F0-8B70-F3A32916CCBB

Q36822126-801537BE-F475-41C1-A13A-C0BAE534220A

Q36822126-872FFA99-23B1-4862-87FF-D8AD45EF0FC9

Q36822126-94B56E1B-2D89-4ACA-8F45-0738592CBB08

Q36822126-BF5025BC-D3E0-4732-945C-06C131CECB58

Q36822126-BFE94D8A-320D-49C8-8486-2F599916C9DF

Q36822126-EC64E2AE-CC4B-43BF-831C-3C6B2E8BE2BA

Q36822126-F7FC84BD-C7F0-42A4-A369-5E4CAF6259E9

P2860

Q36822126-084CB5CC-618E-41B4-95FA-12715D3D013F

Q36822126-08D0BF54-3A52-4130-AA3D-742E15E10F15

Q36822126-0C875A75-094C-496B-863E-CECB0C98561F

Q36822126-1861C88D-C861-4355-9E22-89290E35946D

Q36822126-186B72AD-99D9-4BDA-9733-7670463326D4

Q36822126-20A205C1-224C-4B56-8E51-30CA412DA6DD

Q36822126-223BDA05-3A82-46E8-8AC8-49DF98F179A7

Q36822126-2C58694B-065D-4C3A-B7D8-EF0156B4BC84

Q36822126-31355F31-1E7D-4511-80F1-0C3D7070AD8A

Q36822126-315A13DA-A813-4048-A33C-B53B3D3C20B7

P304

Q36822126-8CE224E6-511F-47AF-95E9-4BB3494A088C

P31

Q36822126-60AB66C4-6E4C-4041-B0F6-2BD779293E1A

P356

Q36822126-92E1B4A5-F8C8-4024-9DF7-D3F20E9B430F

P407

Q36822126-1BC93819-B49F-44B9-BC9D-77991AB49E91

P433

Q36822126-5377944F-BF69-4FAD-B73E-442B248084BF

P478

Q36822126-3ED0E872-9C0C-41C3-8E97-6D7D7A173936

P50

Q36822126-4994C5BE-28EC-4D0D-9CC6-DE7DB76EEF50

Q36822126-624F2187-8C12-4EF1-A498-B343EDE91F7D

Q36822126-65C576A9-9B1E-4244-96E9-4D2724364CDD

Q36822126-E5BC1CD1-C649-43A8-9DEF-982385DD5A86

Q36822126-F3F766FB-CE62-44C1-A931-917A7AE696BF

Q36822126-FD0FACFB-9AF1-4A29-98C0-F55368EA1C52

Q36822126-FDF21791-587D-435F-87D8-3A17FE8F9B5E

P577

Q36822126-633B089A-AF46-4404-9AEF-6FA67E632332

P698

Q36822126-10A8F53A-3172-49C9-98D6-578A8BF46B92

P932

Q36822126-E2C85C0E-A8BE-4F2A-8ED7-061ABC6AF1AB

P356

JCO.2011.41.1660

P1433

Journal of Clinical Oncology

P1476

Atypical melanocytic prolifera ...... oing selective BRAF inhibition

@en

P2093

Axel Hauschild

http://www.w3.org/2001/XMLSchema#string

Elisabeth Livingstone

http://www.w3.org/2001/XMLSchema#string

Friederike Egberts

http://www.w3.org/2001/XMLSchema#string

Klaus Busam

http://www.w3.org/2001/XMLSchema#string

Lisa Zimmer

http://www.w3.org/2001/XMLSchema#string

Mohammed Kashani-Sabet

http://www.w3.org/2001/XMLSchema#string

Reinhard Dummer

http://www.w3.org/2001/XMLSchema#string

Richard D Carvajal

http://www.w3.org/2001/XMLSchema#string

Simone M Goldinger

http://www.w3.org/2001/XMLSchema#string

Uwe Hillen

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

P304

2375-2383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.41.1660

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Schadendorf

Georgina V. Long

Mario E Lacouture

P577

2012-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22614973

http://www.w3.org/2001/XMLSchema#string

P932

3646308

http://www.w3.org/2001/XMLSchema#string